Updates are available Correction dated 2024-06-25
Click to view Correction: https://doi.org/10.1038/s41587-024-02318-9
-
Authors
Pétremand, Rémy http://orcid.org/0000-0002-7629-7336
Chiffelle, Johanna http://orcid.org/0000-0002-8312-2681
Bobisse, Sara
Perez, Marta A. S.
Schmidt, Julien
Arnaud, Marion http://orcid.org/0000-0003-0534-2379
Barras, David http://orcid.org/0000-0001-8985-4704
Lozano-Rabella, Maria http://orcid.org/0000-0002-6304-3919
Genolet, Raphael http://orcid.org/0000-0001-9335-3945
Sauvage, Christophe
Saugy, Damien
Michel, Alexandra
Huguenin-Bergenat, Anne-Laure
Capt, Charlotte
Moore, Jonathan S. http://orcid.org/0000-0002-7586-671X
De Vito, Claudio
Labidi-Galy, S. Intidhar
Kandalaft, Lana E. http://orcid.org/0000-0002-1575-6674
Dangaj Laniti, Denarda
Bassani-Sternberg, Michal http://orcid.org/0000-0002-1934-954X
Oliveira, Giacomo http://orcid.org/0000-0001-7435-5603
Wu, Catherine J.
Coukos, George http://orcid.org/0000-0001-8813-7367
Zoete, Vincent http://orcid.org/0000-0002-2336-6537
Harari, Alexandre http://orcid.org/0000-0002-1055-2090
- License Information
-
More Information
Article History
Received: 7 November 2023
Accepted: 2 April 2024
First Online: 7 May 2024
Change Date: 25 June 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41587-024-02318-9
Competing interests
: V.Z. is a consultant for Cellestia Biotech. G.C. has received grants or research support from or is a coinvestigator in clinical trials by Bristol-Myers-Squibb, Celgene, Boehringer Ingelheim, Tigen, Roche, Iovance and Kite. G.C. has received honoraria for consultations or presentations from Roche, Genentech, BMS, AstraZeneca, Sanofi-Aventis, Nextcure and GeneosTx. G.C. has patents in the domain of antibodies and vaccines targeting the tumor vasculature as well as technologies related to T cell expansion and engineering for T cell therapy. G.C. receives royalties from the University of Pennsylvania. S.B., G.C. and A.H. are inventors in technologies related to T cell expansion and engineering for T cell therapy. R.G is inventor on a patent related to TCR sequencing. A.H., R.P., V.Z., M.A.S.P. and G.C. are inventors on patent applications filed under certain subject matters disclosed herein. The remaining authors declare no competing interests.
